Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...